TSHATaysha Gene Therapies, Inc.
$4.49+59% 1Y
$4.49
$2.8752 weeks$6.98
The financials
Taysha Gene Therapies, Inc. by the numbers
Taysha Gene Therapies, Inc. (TSHA) reported revenue of $0 in Q2 2026 (quarter ended Jun 30, 2026), down 100% from the same quarter a year earlier. That came with net loss of $47M. For the full year FY2025, revenue was $9.8M (+17% year on year) and net income −$109M. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $0 | $2.0M | to a loss |
| Operating income | −$47M | −$27M | n/a |
| Net income | −$47M | −$27M | n/a |
| Diluted EPS | −$0.13 | −$0.09 | n/a |
On our screens:Most shorted stocks